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Sir,
We are grateful to Eggener et al (2009) for their interest in our
article on using high-intensity-focused ultrasound (HIFU) to treat
localised prostate cancer (Ahmed et al, 2009). We agree that
existing treatments are unlikely to achieve the ideal trifecta of low
incontinence, low erectile dysfunction and good cancer control.
This is despite the trend towards increased specification and costs
(intensity-modulated radiotherapy; robotic/laparoscopic radical
prostatectomy). It is for this reason that we began to explore HIFU
as a possible alternative.
We are grateful to Eggener et al for commending us on our
efforts. We have attempted to report all outcomes, both functional
and cancer control, in as robust a manner as the dataset allowed.
Indeed, to this end, we chose a number of definitions of bio-
chemical failure and analysed functional outcomes at a number
of thresholds so as to ensure that readers were not misled with
respect to patient-reported outcome measures and that the
denominator patient group was looked at. These efforts were all
in order to allow the reader to derive the true value and place
of HIFU in the treatment of prostate cancer. We do reiterate that
this was not a prospective study but represents an important
cohort in that they were the first to be treated within the UK. As a
result, our series has a number of interventions (the conduct of the
HIFU evolved); it contains a spectrum of risk from as low as T1c
to as high as T3a, as well as numerous learning curves. It therefore
represents what could be achieved in a pragmatic real-practice
setting. We did our best to explain this so that the reader was
aware of the limitations of the study.
However, one should not underestimate the value of a treatment
that can be delivered in a day-case setting, be repeated and deliver
very low rates of incontinence for a disease in which 48 men need
to be treated in order to save the life of one man over 10 years
(Schroder et al, 2009). We agree that the impotence rates were not
as encouraging as we would have liked. Indeed, our focus at
present is on using the attributes of HIFU to treat in a focal
manner with phase II prospective ethically approved trials close to
completion (Ahmed et al, 2007; Ahmed, 2009). This seems to us
and many others to be the most plausible way in which we can
achieve the ‘perfect result’ for the majority of men who are
currently subject to much harm.
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